T. Rowe Price Investment Management Inc. Sells 1,141,155 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• T. Rowe Price Investment Management Inc. has reduced its stake in Thermo Fisher Scientific by 37.0%, now holding approximately 1,942,745 shares worth around $966.7 million.
• In the latest quarter, multiple hedge funds have initiated positions in Thermo Fisher Scientific, indicating strong institutional interest in the company.
• Thermo Fisher Scientific reported earnings of $5.36 per share, exceeding analyst expectations, with a revenue of $10.86 billion for the quarter.

T. Rowe Price Investment Management Inc. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 37.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 1,942,745 shares of the medical research company's stock after selling 1,141,155 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 0.51% of Thermo Fisher Scientific worth $966,710,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TMO. GAMMA Investing LLC lifted its position in shares of Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the period. Nuveen LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter worth about $532,360,000. Kovitz Investment Group Partners LLC increased its holdings in Thermo Fisher Scientific by 1,905.4% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after purchasing an additional 858,193 shares in the last quarter. Farallon Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 73.8% in the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after buying an additional 523,800 shares during the period. Finally, Sarasin & Partners LLP acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $242,991,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on TMO. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 10th. Argus cut their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. HSBC restated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Royal Bank Of Canada dropped their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Evercore ISI dropped their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded up $16.4780 during midday trading on Friday, hitting $500.2380. 1,778,365 shares of the company's stock were exchanged, compared to its average volume of 2,406,376. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock has a 50-day moving average price of $443.02 and a two-hundred day moving average price of $457.46. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company has a market cap of $188.89 billion, a P/E ratio of 28.93, a PEG ratio of 2.58 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the business earned $5.37 earnings per share. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,896 shares of company stock valued at $8,593,838 over the last quarter. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.